NMR metabolomic profiles associated with long-term risk of prostate cancer.
Metabolomics
Nuclear magnetic resonance
Prospective study
Prostate cancer risk
Journal
Metabolomics : Official journal of the Metabolomic Society
ISSN: 1573-3890
Titre abrégé: Metabolomics
Pays: United States
ID NLM: 101274889
Informations de publication
Date de publication:
11 03 2021
11 03 2021
Historique:
received:
26
08
2020
accepted:
24
02
2021
entrez:
11
3
2021
pubmed:
12
3
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Prostate cancer is a multifactorial disease whose aetiology is still not fully understood. Metabolomics, by measuring several hundred metabolites simultaneously, could enhance knowledge on the metabolic changes involved and the potential impact of external factors. The aim of the present study was to investigate whether pre-diagnostic plasma metabolomic profiles were associated with the risk of developing a prostate cancer within the following decade. A prospective nested case-control study was set up among the 5141 men participant of the SU.VI.MAX cohort, including 171 prostate cancer cases, diagnosed between 1994 and 2007, and 171 matched controls. Nuclear magnetic resonance (NMR) metabolomic profiles were established from baseline plasma samples using NOESY1D and CPMG sequences. Multivariable conditional logistic regression models were computed for each individual NMR signal and for metabolomic patterns derived using principal component analysis. Men with higher fasting plasma levels of valine (odds ratio (OR) = 1.37 [1.07-1.76], p = .01), glutamine (OR = 1.30 [1.00-1.70], p = .047), creatine (OR = 1.37 [1.04-1.80], p = .02), albumin lysyl (OR = 1.48 [1.12-1.95], p = .006 and OR = 1.51 [1.13-2.02], p = .005), tyrosine (OR = 1.40 [1.06-1.85], p = .02), phenylalanine (OR = 1.39 [1.08-1.79], p = .01), histidine (OR = 1.46 [1.12-1.88], p = .004), 3-methylhistidine (OR = 1.37 [1.05-1.80], p = .02) and lower plasma level of urea (OR = .70 [.54-.92], p = .009) had a higher risk of developing a prostate cancer during the 13 years of follow-up. This exploratory study highlighted associations between baseline plasma metabolomic profiles and long-term risk of developing prostate cancer. If replicated in independent cohort studies, such signatures may improve the identification of men at risk for prostate cancer well before diagnosis and the understanding of this disease.
Identifiants
pubmed: 33704614
doi: 10.1007/s11306-021-01780-9
pii: 10.1007/s11306-021-01780-9
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
32Références
Assi, N. (2015). A statistical framework to model the meeting-in-the-middle principle using metabolomic data: application to hepatocellular carcinoma in the EPIC study. Mutagenesis, 30(6), 743–753. https://doi.org/10.1093/mutage/gev045 .
doi: 10.1093/mutage/gev045
pubmed: 26130468
pmcid: 5909887
Assi, N., Thomas, D. C., Leitzman, M., Stepien, M., Chajes, V., Philip, T., et al. (2018). Are metabolic signatures mediating the relationship between lifestyle factors and hepatocellular carcinoma risk? Results from a nested case-control study in EPIC. Cancer Epidemiology, Biomarkers & Prevention, 27(5), 531–540. https://doi.org/10.1158/1055-9965.EPI-17-0649 .
Athersuch, T. J., & Keun, H. C. (2015). Metabolic profiling in human exposome studies. Mutagenesis, 30(6), 755–762. https://doi.org/10.1093/mutage/gev060 .
doi: 10.1093/mutage/gev060
pubmed: 26290610
Benjamini, Y., & Hochberg, Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B, 57(1), 289–300.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. https://doi.org/10.3322/caac.21492 .
doi: 10.3322/caac.21492
Bro, R., Kamstrup-Nielsen, M. H., Engelsen, S. B., Savorani, F., Rasmussen, M. A., Hansen, L., et al. (2015). Forecasting individual breast cancer risk using plasma metabolomics and biocontours. Metabolomics, 11(5), 1376–1380.
doi: 10.1007/s11306-015-0793-8
Brockmoller, S. F., Bucher, E., Muller, B. M., Budczies, J., Hilvo, M., Griffin, J. L., et al. (2012). Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer-link to patient survival, hormone receptor status, and metabolic profiling. Journal of Proteome Research, 11, 850–860.
doi: 10.1021/pr200685r
Budczies, J., Brockmoller, S. F., Muller, B. M., Barupal, D. K., Richter-Ehrenstein, C., Kleine-Tebbe, A., et al. (2013). Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: Alterations in glutamine and beta-alanine metabolism. Journal of Proteomics, 94C, 279–288.
doi: 10.1016/j.jprot.2013.10.002
Carayol, M., Licaj, I., Achaintre, D., Sacerdote, C., Vineis, P., Key, T. J., et al. (2015). Reliability of serum metabolites over a two-year period: A targeted metabolomic approach in fasting and non-fasting samples from EPIC. PLoS ONE, 10, e0135437.
Carr, H. Y., & Purcell, E. M. (1954). Effects of diffusion on free precession in nuclear magnetic resonance experiments. Physical Review, 94, 630–638.
doi: 10.1103/PhysRev.94.630
Cattell, R. B. (1966). The scree test for the number of factors. Multivariate Behavioral Research, 1, 245–276.
doi: 10.1207/s15327906mbr0102_10
Claudino, W. M., Quattrone, A., Biganzoli, L., Pestrin, M., Bertini, I., & Di, L. A. (2007). Metabolomics: Available results, current research projects in breast cancer, and future applications. Journal of Clinical Oncology, 25, 2840–2846.
doi: 10.1200/JCO.2006.09.7550
Costello, L. C., & Franklin, R. B. (2000). The intermediary metabolism of the prostate: A key to understanding the pathogenesis and progression of prostate malignancy. Oncology (Williston Park, N.Y.), 59(4), 269–282. https://doi.org/10.1159/000012183 .
doi: 10.1159/000012183
Defossez, G., Le Guyader–Peyrou, S., Uhry, Z., Grosclaude, P., Colonna, M., & Dantony, E. (2019). Estimations nationales de l’incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018. In Synthèse (p. 20). Santé publique France.
Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., & Bax, A. (1995). NMRPipe: A multidimensional spectral processing system based on UNIX pipes. Journal of Biomolecular NMR, 6, 277–293.
doi: 10.1007/BF00197809
Eidelman, E., Twum-Ampofo, J., Ansari, J., & Siddiqui, M. M. (2017). The metabolic phenotype of prostate cancer. Frontiers in Oncology, 7, 131. https://doi.org/10.3389/fonc.2017.00131 .
doi: 10.3389/fonc.2017.00131
pubmed: 28674679
pmcid: 5474672
Fages, A., Duarte-Salles, T., Stepien, M., Ferrari, P., Fedirko, V., Pontoizeau, C., et al. (2015). Metabolomic profiles of hepatocellular carcinoma in a European prospective cohort. BMC Medicine, 13, 242. https://doi.org/10.1186/s12916-015-0462-9 .
doi: 10.1186/s12916-015-0462-9
pubmed: 26399231
pmcid: 4581424
Floegel, A., Drogan, D., Wang-Sattler, R., Prehn, C., Illig, T., Adamski, J., et al. (2011). Reliability of serum metabolite concentrations over a 4-month period using a targeted metabolomic approach. PLoS ONE, 6, e21103.
Giraudeau, P., Silvestre, V., & Akoka, S. (2015). Optimizing water suppression for quantitative NMR-based metabolomics: a tutorial review. Metabolomics, 11(5), 1041–1055.
Guenin, S., Schwartz, L., Morvan, D., Steyaert, J. M., Poignet, A., Madelmont, J. C., & Demidem, A. (2008). PP2A activity is controlled by methylation and regulates oncoprotein expression in melanoma cells: A mechanism which participates in growth inhibition induced by chloroethylnitrosourea treatment. International Journal of Oncology, 32, 49–57.
pubmed: 18097542
Hercberg, S., Galan, P., Preziosi, P., Bertrais, S., Mennen, L., Malvy, D., et al. (2004). The SU.VI.MAX study: A randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Archives of Internal Medicine, 164, 2335–2342.
doi: 10.1001/archinte.164.21.2335
Hercberg, S., Preziosi, P., Briancon, S., Galan, P., Triol, I., Malvy, D., et al. (1998). A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: the SU.VI.MAX study–design, methods, and participant characteristics. SUpplementation en VItamines et Mineraux AntioXydants. Controlled Clinical Trials, 19, 336–351.
doi: 10.1016/S0197-2456(98)00015-4
Howell, A. (2010). Can metabolomics in addition to genomics add to prognostic and predictive information in breast cancer? BMC Medicine, 8, 73.
doi: 10.1186/1741-7015-8-73
Huang, J., Mondul, A. M., Weinstein, S. J., Koutros, S., Derkach, A., Karoly, E., et al. (2016). Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. British Journal of Cancer, 115, 1087–1095.
doi: 10.1038/bjc.2016.305
Jobard, E., Pontoizeau, C., Blaise, B. J., Bachelot, T., Elena-Herrmann, B., & Tredan, O. (2014). A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer. Cancer Letters, 343, 33–41.
doi: 10.1016/j.canlet.2013.09.011
Koutros, S., Meyer, T. E., Fox, S. D., Issaq, H. J., Veenstra, T. D., Huang, W.-Y., et al. (2013). Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Carcinogenesis, 34(10), 2281–2285. https://doi.org/10.1093/carcin/bgt176 .
doi: 10.1093/carcin/bgt176
pubmed: 23698636
pmcid: 3786375
Kuhn, T., Floegel, A., Sookthai, D., Johnson, T., Rolle-Kampczyk, U., Otto, W., et al. (2016). Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics study. BMC Medicine, 14, 13.
doi: 10.1186/s12916-016-0552-3
Kühn, T., Sookthai, D., Graf, M. E., Schübel, R., Freisling, H., Johnson, T., et al. (2017). Albumin, bilirubin, uric acid and cancer risk: Results from a prospective population-based study. British Journal of Cancer, 117(10), 1572–1579. https://doi.org/10.1038/bjc.2017.313 .
doi: 10.1038/bjc.2017.313
pubmed: 28898231
pmcid: 5680462
Lécuyer, L., Dalle, C., Lyan, B., Demidem, A., Rossary, A., Vasson, M.-P., et al. (2019). Plasma metabolomic signatures associated with long-term breast cancer risk in the SU.VI.MAX prospective cohort. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. https://doi.org/10.1158/1055-9965.EPI-19-0154 .
Lécuyer, L., Bala, V., Deschasaux, A., Bouchemal, M., Triba, N. Nawfal, Vasson, M., M.-P., et al (2018). NMR metabolomic signatures reveal predictive plasma metabolites associated with long-term risk of developing breast cancer. International Journal of Epidemiology, 47(2), 484–494. https://doi.org/10.1093/ije/dyx271 .
doi: 10.1093/ije/dyx271
pubmed: 29365091
Leverve, X., Carpentier, F., Barnoud, D., Fontaine, E., & Guignier, M. (1992). Intérêt et limites de la 3-méthylhistidine pour la mesure du catabolisme musculaire. Nutrition Clinique et Métabolisme, 6(4), 219–225. https://doi.org/10.1016/S0985-0562(05)80371-1 .
doi: 10.1016/S0985-0562(05)80371-1
Liesenfeld, D. B., Habermann, N., Owen, R. W., Scalbert, A., & Ulrich, C. M. (2013). Review of mass spectrometry-based metabolomics in cancer research. Cancer Epidemiology, Biomarkers & Prevention, 22, 2182–2201.
doi: 10.1158/1055-9965.EPI-13-0584
Lucarelli, G., Loizzo, D., Ferro, M., Rutigliano, M., Vartolomei, M. D., Cantiello, F., et al. (2019). Metabolomic profiling for the identification of novel diagnostic markers and therapeutic targets in prostate cancer: An update. Expert Review of Molecular Diagnostics, 19(5), 377–387. https://doi.org/10.1080/14737159.2019.1604223 .
doi: 10.1080/14737159.2019.1604223
pubmed: 30957583
Lucarelli, G., Rutigliano, M., Galleggiante, V., Giglio, A., Palazzo, S., Ferro, M., et al. (2015). Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer. Expert Review of Molecular Diagnostics, 15(9), 1211–1224. https://doi.org/10.1586/14737159.2015.1069711 .
doi: 10.1586/14737159.2015.1069711
pubmed: 26174441
Magnusson, M., Lewis, G. D., Ericson, U., Orho-Melander, M., Hedblad, B., Engstrom, G., et al. (2013). A diabetes-predictive amino acid score and future cardiovascular disease. European Heart Journal, 34, 1982–1989.
doi: 10.1093/eurheartj/ehs424
Maxeiner, A., Adkins, C. B., Zhang, Y., Taupitz, M., Halpern, E. F., McDougal, W. S., et al. (2010). Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles. Prostate, 70, 710–717.
pubmed: 20017167
pmcid: 2909586
Merlot, A. M., Kalinowski, D. S., & Richardson, D. R. (2014). Unraveling the mysteries of serum albumin-more than just a serum protein. Frontiers in Physiology, 5, 299. https://doi.org/10.3389/fphys.2014.00299 .
doi: 10.3389/fphys.2014.00299
pubmed: 25161624
pmcid: 4129365
Mondul, A. M., Moore, S. C., Weinstein, S. J., Karoly, E. D., Sampson, J. N., & Albanes, D. (2015). Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha-tocolpherol, beta-carotene cancer prevention (ATBC) study. International Journal of Cancer, 137, 2124–2132.
doi: 10.1002/ijc.29576
Mondul, A. M., Moore, S. C., Weinstein, S. J., Mannisto, S., Sampson, J. N., & Albanes, D. (2014). 1-stearoylglycerol is associated with risk of prostate cancer: Results from serum metabolomic profiling. Metabolomics, 10, 1036–1041.
doi: 10.1007/s11306-014-0643-0
Newgard, C. B., An, J., Bain, J. R., Muehlbauer, M. J., Stevens, R. D., Lien, L. F., et al. (2009). A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metabolism, 9, 311–326.
doi: 10.1016/j.cmet.2009.02.002
O’Connell, T. M. (2013). The complex role of branched chain amino acids in diabetes and cancer. Metabolites, 3, 931–945.
doi: 10.3390/metabo3040931
Ren, J.-G., Seth, P., Ye, H., Guo, K., Hanai, J.-I., Husain, Z., & Sukhatme, V. P. (2017). Citrate Suppresses tumor growth in multiple models through inhibition of glycolysis, the tricarboxylic acid cycle and the IGF-1R pathway. Scientific Reports, 7(1), 4537. https://doi.org/10.1038/s41598-017-04626-4 .
doi: 10.1038/s41598-017-04626-4
pubmed: 28674429
pmcid: 5495754
Scalbert, A., Brennan, L., Manach, C., Andres-Lacueva, C., Dragsted, L. O., Draper, J., et al. (2014). The food metabolome: A window over dietary exposure. The American Journal of Clinical Nutrition, 99(6), 1286–1308.
doi: 10.3945/ajcn.113.076133
Schmidt, J. A., Fensom, G. K., Rinaldi, S., Scalbert, A., Appleby, P. N., Achaintre, D., et al. (2017). Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation into Cancer and Nutrition. BMC Medicine, 15(1), 122. https://doi.org/10.1186/s12916-017-0885-6 .
doi: 10.1186/s12916-017-0885-6
pubmed: 28676103
pmcid: 5497352
Sousa, S. A., Magalhaes, A., & Ferreira, M. M. (2013). Optimized bucketing for NMR spectra: Three case studies. Chemometrics and Intelligent Laboratory Systems, 122, 93–102.
doi: 10.1016/j.chemolab.2013.01.006
Sreekumar, A., Poisson, L. M., Rajendiran, T. M., Khan, A. P., Cao, Q., Yu, J., et al. (2009). Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature, 457, 910–914.
doi: 10.1038/nature07762
Stepien, M., Duarte-Salles, T., Fedirko, V., Floegel, A., Barupal, D. K., Rinaldi, S., et al. (2016). Alteration of amino acid and biogenic amine metabolism in hepatobiliary cancers: Findings from a prospective cohort study. International Journal of Cancer, 138, 348–360.
doi: 10.1002/ijc.29718
Vandenbroucke, J. P., & Pearce, N. (2012). Case-control studies: Basic concepts. International Journal of Epidemiology, 41(5), 1480–1489. https://doi.org/10.1093/ije/dys147 .
doi: 10.1093/ije/dys147
pubmed: 23045208
WHO. (1993). ICD-10, International Classification of Diseases and related health problems, 10th revision. World Health Organization.
Wishart, D. S., Feunang, Y. D., Marcu, A., Guo, A. C., Liang, K., Vázquez-Fresno, R., et al. (2018). HMDB 4.0: The human metabolome database for 2018. Nucleic Acids Research, 46(D1), D608–D617. https://doi.org/10.1093/nar/gkx1089 .
doi: 10.1093/nar/gkx1089
pubmed: 29140435
Wood, S. L., Westbrook, J. A., & Brown, J. E. (2014). Omic-profiling in breast cancer metastasis to bone: Implications for mechanisms, biomarkers and treatment. Cancer Treatment Reviews, 40, 139–152.
doi: 10.1016/j.ctrv.2013.07.006
World Cancer Research Fund/American Institute for Cancer Research. (2014). Continuous Update Project Expert Report 2018. Diet, nutrition, physical activity and prostate cancer. World Cancer Research Fund/American Institute for Cancer Research.
World Cancer Research Fund/American Institute for Cancer Research. (2018). Continuous Update Project Expert Report 2018. The cancer process. http://www.dietandcancerreport.org .
Wu, S., Zhu, W., Thompson, P., & Hannun, Y. A. (2018). Evaluating intrinsic and non-intrinsic cancer risk factors. Nature Communications, 9(1), 3490. https://doi.org/10.1038/s41467-018-05467-z .
doi: 10.1038/s41467-018-05467-z
pubmed: 30154431
pmcid: 6113228
Wurtz, P., Soininen, P., Kangas, A. J., Ronnemaa, T., Lehtimaki, T., Kahonen, M., et al. (2013). Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care, 36(3), 648–655. https://doi.org/10.2337/dc12-0895 .
doi: 10.2337/dc12-0895
pubmed: 23129134
pmcid: 3579331